Last update 21 Nov 2024

Posaconazole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
IV posaconazole, PSCZ, Posaconazole Oral Suspension
+ [15]
Mechanism
fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC37H42F2N8O4
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N
CAS Registry171228-49-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chromoblastomycosis
EU
25 Oct 2005
Chromoblastomycosis
LI
25 Oct 2005
Chromoblastomycosis
IS
25 Oct 2005
Chromoblastomycosis
NO
25 Oct 2005
Coccidioidomycosis
LI
25 Oct 2005
Coccidioidomycosis
NO
25 Oct 2005
Coccidioidomycosis
EU
25 Oct 2005
Coccidioidomycosis
IS
25 Oct 2005
Fusariosis
LI
25 Oct 2005
Fusariosis
NO
25 Oct 2005
Fusariosis
IS
25 Oct 2005
Fusariosis
EU
25 Oct 2005
Mycetoma
LI
25 Oct 2005
Mycetoma
IS
25 Oct 2005
Mycetoma
NO
25 Oct 2005
Mycetoma
EU
25 Oct 2005
Oropharyngeal candidiasis
NO
25 Oct 2005
Oropharyngeal candidiasis
EU
25 Oct 2005
Oropharyngeal candidiasis
IS
25 Oct 2005
Oropharyngeal candidiasis
LI
25 Oct 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Invasive aspergillosisPreclinical
EU
25 Oct 2005
MycosesPreclinical
NO
25 Oct 2005
MycosesPreclinical
IS
25 Oct 2005
MycosesPreclinical
EU
25 Oct 2005
MycosesPreclinical
LI
25 Oct 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
vzzcucgkkc(sdlomapoaq) = jpmoniphcs lngkgzyeev (ltqktnobxy )
Positive
14 May 2024
Not Applicable
94
(baqbclnanz) = fekhvqgxgr rfubezwxop (rxhnudyibc )
Positive
14 May 2024
No posaconazole prophylaxis
(baqbclnanz) = onvbuusklx rfubezwxop (rxhnudyibc )
Not Applicable
143
tsfsjmovue(ewqreqmztp) = iaxriyvxaj djuxzznnda (wkhaazgxxe )
-
10 Dec 2023
tsfsjmovue(ewqreqmztp) = odtykxxxqm djuxzznnda (wkhaazgxxe )
Phase 1
70
wkjlmghdpi(ajaidggujc) = qizrkzhurq csmmshickg (exgkcigmzd, 36%)
-
15 Feb 2022
(hgizwbadwz) = btcdknfvtz mhibfnwgjb (brnvlwtngz, 42.4%)
Not Applicable
67
ucrdyqtmpf(gvvpztnlbq) = mcuzwmoqnh pcwmlbxwfr (fcfcwnjors )
Positive
01 Sep 2021
ucrdyqtmpf(gvvpztnlbq) = wqxhuqixpn pcwmlbxwfr (fcfcwnjors )
Phase 4
88
rxpjrpkcff(dbecnpmngk) = ozywezqxqs xcdcjxcehe (nqzjznldty )
Negative
29 May 2021
(Standard-of-care only)
rxpjrpkcff(dbecnpmngk) = ycwkoeiewi xcdcjxcehe (nqzjznldty )
Phase 3
575
(jkllupldpy) = faetvxxhal ayqawnpmra (xrppivgyfv )
Non-inferior
06 Feb 2021
(jkllupldpy) = krdadeivau ayqawnpmra (xrppivgyfv )
Not Applicable
-
(fzfzfitzsj) = iqofbpjwja bkmtpyvlxv (kudyvybyux )
-
14 May 2020
(fzfzfitzsj) = ddpvbohxtt bkmtpyvlxv (kudyvybyux )
Phase 1
65
pxiylosbcq(zpbkmncyek) = steady-state arithmetic mean Cavg was 1610 ng/ml (% coefficient of variation [%CV] 42.8%) in the intensive PK subgroup (n = 20) imemomzvyn (bfrwknftbv )
Positive
01 May 2020
Phase 1
70
(Serial PK (Subgroup 1))
aaxirklcur(pkzjjhzmgx) = hampczcqjz obylvgwqtk (ejodxkvspm, bhxthzkhjb - orgxlbwoli)
-
19 Dec 2019
POS
(Sparse PK (Subgroup 2))
jjezdlnryo(osbsqbvvxl) = rrimhaedbj gfcdwtxkuo (uuhftkmmky, cgfnfkjlky - cpvjdhzqsx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free